Dataset Information

A novel polyamine blockade therapy activates an anti-tumor immune response.

ABSTRACT: Most tumors maintain elevated levels of polyamines to support their growth and survival. This study explores the anti-tumor effect of polyamine starvation via both inhibiting polyamine biosynthesis and blocking the upregulated import of polyamines into the tumor. We demonstrate that polyamine blockade therapy (PBT) co-treatment with both DFMO and a novel polyamine transport inhibitor, Trimer PTI, significantly inhibits tumor growth more than treatment with DFMO or the Trimer PTI alone. The anti-tumor effect of PBT was lost in mice where CD4+ and CD8+ T cells were antibody depleted, implying that PBT stimulates an anti-tumor immune effect that is T-cell dependent. The PBT anti-tumor effect was accompanied by an increase in granzyme B+, IFN-?+ CD8+ T-cells and a decrease in immunosuppressive tumor infiltrating cells including Gr-1+CD11b+ myeloid derived suppressor cells (MDSCs), CD4+CD25+ Tregs, and CD206+F4/80+ M2 macrophages. Stimulation with tumor-specific peptides elicited elevated antigen-specific IFN-? secretion in splenocytes from PBT-treated mice, indicating that PBT treatment stimulates the activation of T-cells in a tumor-specific manner. These data show that combined treatment with both DFMO and the Trimer PTI not only deprives polyamine-addicted tumor cells of polyamines, but also relieves polyamine-mediated immunosuppression in the tumor microenvironment, thus allowing the activation of tumoricidal T-cells.

SUBMITTER: Alexander ET

PROVIDER: S-EPMC5663583 | biostudies-literature | 2017 Oct

REPOSITORIES: biostudies-literature

ACCESS DATA

Publications

A novel polyamine blockade therapy activates an anti-tumor immune response.

Alexander Eric T ET Minton Allyson A Peters Molly C MC Phanstiel Otto O Gilmour Susan K SK

Oncotarget 20170824 48

Most tumors maintain elevated levels of polyamines to support their growth and survival. This study explores the anti-tumor effect of polyamine starvation via both inhibiting polyamine biosynthesis and blocking the upregulated import of polyamines into the tumor. We demonstrate that polyamine blockade therapy (PBT) co-treatment with both DFMO and a novel polyamine transport inhibitor, Trimer PTI, significantly inhibits tumor growth more than treatment with DFMO or the Trimer PTI alone. The anti- ...[more]

PMID: 29137411

Similar Datasets

Project description:Galunisertib (Gal) is a transforming growth factor (TGF-β) blockade which is being investigated as a potential tumor immunotherapy candidate drug in clinical trials. However, primary or acquired resistance is often found in the recruited cancer patients, which limits its clinical application. Tumor immune microenvironment can be regulated by intestinal microbiota, leading to different therapeutic outcomes. It is hypothesized that manipulation of cancer patients' intestinal microbiome in the early stage of therapy may be a promising strategy to improve the therapeutic efficacy of Gal. Methods: 4T1 and H22 subcutaneous tumor bearing mice were used to evaluate the therapeutic effect. Escherichia coli strain Nissle 1917 (EcN), a widely used probiotic bacteria, was orally delivered to the tumor bearing mice daily along with Gal treatment. Antitumor effect of the combination therapy was evaluated by tumor volume, histological staining of tumor tissues. Furthermore, flow cytometry was performed to analyze the alteration of immune microenvironment in tumor bed after treatment. The suppressing effect of the combination therapy on tumor invasiveness and metastasis was evaluated in both mice and zebrafish xenografts models. Fecal sample 16S rRNA gene sequencing was conducted to analyze changes of intestinal microbial diversity. The effect of intestinal microbiota on tumor suppression after receiving EcN was further tested by fecal transplant. Results: The therapeutic outcomes in tumor growth inhibition and metastasis suppression of Gal were significantly potentiated by EcN, resulting from the strengthened antitumor immunity. EcN was able to relieve the immunosuppressive tumor microenvironment, which was evidenced by enhanced tumor-specific effector T cells infiltration and dendritic cells activation. Intestinal microbiota was modulated by EcN, illustrated by a shift of gut microbiome toward certain beneficial bacteria. Conclusion: These results suggested that Gal combined with EcN might be a novel therapeutic approach with great potential of clinical implications for cancer prevention or treatment.

Project description:BackgroundImmune checkpoint blockades (ICBs) therapy showed limited efficacy in ovarian cancer management. Increasing evidence indicated that conventional and targeted therapies could affect tumor-associated immune responses and increase the effectiveness of immunotherapy. However, the effects of Niraparib, one of the poly (ADP) ribose polymerase (PARP) inhibitors, on the immune response remains unclear. Delineating the crosstalk between cytotoxic anticancer agents and cancer-associated immunity may lead to more efficient combinatorial strategies.MethodsProgrammed death ligand 1 (PD-L1) expression in human ovarian cancer cells after PARP inhibitors treatment was examined by western blotting (WB) and flow cytometry. The expression of poly ADP-ribose polymerase (PARP1), PD-L1, and CD8 in human ovarian cancer tissues was detected by immunohistochemistry(IHC). The effect of Niraparib and PD-L1 blockade in ovarian cancer progression was investigated in vivo. The changes of immune cells and cytokines in vitro and in vivo were detected by flow cytometry and enzyme-linked immunosorbent assay (ELISA). Changes of cGAS/STING signal pathway after Niraparib treatment were determined by WB, ELISA.ResultsNiraparib upregulated membrane PD-L1 and total PD-L1 expression in ovarian cancer cells and had a synergistic effect with PD-L1 blockade in vivo. In clinical patient samples, Niraparib augmented cytotoxic CD8+T cell proportion and function. In vivo and vitro, Niraparib can also increase the proportion of T cells and combined with PD-L1 blockade could further enhance the effect. Besides, Niraparib activated the cGAS-STING pathway, increasing the levels of cytokines such as CCL5 and CXCL10, which played a vital role in augmenting the infiltration and activation of cytotoxic T cells.ConclusionsNiraparib could modulate the immune response via the activation of the cGAS/STING pathway, and combination with PD-L1 blockade could further enhance the effect. These results provide a sound theoretical basis for clinical treatment.

Project description:IL-21-αHSA combined with TIGIT blockade induces an effective anti-tumor immune response, indicated by the significant enrichment of pathways associated with anti-tumor immune response, as well as significantly increased expression of key genes associated with CD8+ T and NK cell cytotoxicity To further understand the mechanisms by which IL-21-αHSA enhances the benefit of TIGIT blockade, we analyzed MC38 tumor tissues 20 days after five doses of both single agent and combination treatments by RNA sequencing (RNA-seq) of 28,758 genes. Compared to isotype control treatment, combination treatment resulted in 764 genes with differential expression (defined as P < 0.05 and fold change > 2.0), while IL-21-αHSA treatment resulted in 402 DEGs and anti-mTIGIT treatment resulted in 528 DEGs (data not shown). These findings suggest that the combination treatment had a more dramatic effect on gene expression than IL-21-αHSA or anti-mTIGIT treatment alone. To evaluate the pathways underlying the synergistic anti-tumor efficacy induced by the combination treatment, we performed Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway significance enrichment analysis (defined as P adjust < 0.05). In comparison to the isotype control treatment, 41 KEGG pathways were significantly enriched in the combination treatment group (Table S1) and 31 pathways were significantly enriched in the IL-21-αHSA treatment group (Table S2), of which 28 KEGG enrichment pathways overlapped. Additionally, only 8 KEGG pathways were significantly enriched in the anti-mTIGIT treatment group (Table S3), of which 5 KEGG enrichment pathways overlapped with those of the combination treatment group. These findings suggest that IL-21-αHSA in combination with anti-mTIGIT treatment enriched more KEGG pathways with differential gene expression than for monotherapy, and most of the KEGG pathways significantly enriched by the combination treatment were also differentially enriched by IL-21-αHSA treatment alone. The top 15 pathways, ranked in order of significance, are shown in Fig. 7A. As expected, most are associated with classical anti-tumor immunity signal pathways, including the cytokine-cytokine receptor interaction pathway, the viral protein interaction with cytokine and cytokine receptor pathway, the Th1 and Th2 cell differentiation pathway, the antigen processing and presentation pathway, the T cell receptor signaling pathway, and the PD-L1 expression and PD-1 checkpoint pathway in cancer (P adjust < 0.0001). The natural killer cell mediated cytotoxicity pathway was also significantly enriched (P adjust = 0.0059) in the combination treatment group compared to isotype control treatment group, but was not among the top 15 pathways. Overall, these findings suggest that IL-21-αHSA in combination with TIGIT blockade treatment significantly affects the anti-tumor immunity signal in the tumor micro-environment. For further verification, we analyzed the gene expression levels of key effector molecules, including Interferon-γ (IFNG), Granzyme A (Gzma), Granzyme B (Gzmb), and Perforin 1 (Prf1), each of which are critical mediators of CD8+ T cell and NK cell cytotoxicity and are known to play critical roles in anti-tumor response. As shown in Fig. 7B-E, the combination treatment significantly increased the expression of all four genes (P < 0.05) relative to isotype control treatment, though only IFNG and Gzma were differentially expressed in the combination treatment group relative to the anti-mTIGIT group (P < 0.05). Collectively, these results suggest that IL-21-αHSA in combination with TIGIT blockade induces an effective anti-tumor immune response, indicated by the significant enrichment of pathways associated with anti-tumor immune response, as well as significantly increased expression of key genes associated with CD8+ T and NK cell cytotoxicity.

Dataset Information

A novel polyamine blockade therapy activates an anti-tumor immune response.

Publications

A novel polyamine blockade therapy activates an anti-tumor immune response.

Similar Datasets

OmicsDI is part of the ELIXIR infrastructure